Patrick Campbell

Todd Hobbs, MD, chief medical officer of Novo Nordisk North America, discusses the results of PIONEER 4 at ADA 2019 in San Francisco, CA.

Todd Hobbs, MD, chief medical officer at Novo Nordisk North America, discusses what prompted Novo Nordisk to create oral semaglutide.

Todd Hobbs, MD, CMO of Novo Nordisk, discusses the findings of the PIONEER 2 study.

Investigators found that expansion states had a median of 4.3 fewer deaths per 100,000 residents than nonexpansion states.

Amarin announced the FDA had granted their sNDA for icosapent ethyl to reduce residual CV risk in patients with statin-managed LDL-C cholesterol.

A recent study found that dietary supplements for weight loss, energy, and muscle building were associated with a 3 times greater risk of severe medical events than vitamins.

Analyses of more than 2 million patients found that preterm and early births were associated with an increased risk of ischemic heart disease.

A recent study examines the association between new-onset atrial fibrillation and aortic valve replacements and transcatheter aortic valve implantations.

FDA has approved an sNDA for caftolozane/tezobactam for treatment of nosocomial pneumonia.

A study of more than 74,000 in China from 2006 to 2015 found that cardiovascular health scores are associated with subsequent risk of CVD events.

A recent study has found that consumption of coffee may not be as bad as previous studies have portrayed.

Investigators from St. Jude's Children Research Hospital presented the results of the phase 1 trial at ASCO 2019 in Chicago.

Investigators conducted an open-label, randomized, multi-center phase 2 study of VIT and vincristine with irinotecan without temozolomide that included 120 patients from 37 European centers.

A study presented at ASCO 2019 examined the differences between hospitalization cost and length of stay among pancreatic cancer patients based on location of the disease.

Preston Klassen, MD, executive vice president of Arena Pharmaceuticals, discusses potential uses for etrasimod outside of inflammatory bowel disease

FDA approved addition of OS to labeling based on results of the ADMIRAL trial.

Preston Klassen, MD, head of research and development at Arena Pharmaceuticals, discusses olorinab's efficacy and safety for the treatment of abdominal pain in Crohn's disease.

Preston Klassen, MD, head of research and development at Arena Pharmaceuticals, discusses a post hoc analysis of biomarkers and clinical outcomes in patients with ulcerative colitis receving etrasimod.

Investigators found that patients receiving cariprazine showed significant improvement in cognitive symptoms compared to patients receiving aripiprazole or placebo therapy.

Allergan announced the FDA approved a New Drug Application for Vraylar for the treatment of depressive episodes associated with bipolar depression.

Preston Klassen, MD, head of research and development at Arena Pharamaceuticals, discusses mucosal healing and histologic remission in patients with ulcerative colitis receiving etrasimod.

Steven Adelsheim, MD, discusses what he believes is the need to further recognize that many mental health conditions begin to develop at a young age.

Investigators presented 2 pooled analyses at APA 2019 that explored the safety profile and efficacy of 42mg lumateperone in patients with schizophrenia

Investigators presented the results of a 4-week trial examining the efficacy of SEP-363856 at APA 2019 in San Francisco, CA.

Lori Raney, MD, of Health Management Associates in Colorado, sat down with us at APA 2019 to discuss how clinicians should address the mental health needs of an aging population.

Investigators presented data from a 2-year, open-label study into the efficacy and safety of lurasidone in children 10 to 17 years old at APA 2019.

Godfrey Pearlson, MD, founding director of the division of psychiatry neuroimaging at Johns Hopkins University, discusses the possibility of using neuroimaging to diagnose psychiatric disorders.

Lori Raney, MD, psychiatrist and principal with Health Management Associates in CO, discuss what she believes is the most important discussion topic at APA 2019.

Godfrey Pearlson sat down at APA 2019 to discuss his opinion on what the most significant recent advances in neuropsychiatry have been and how they have impacted practice.

Jonathan Avery, MD, addiction psychiatrist and associate professor of psychiatry, sat down with MD Magazine at APA 2019 to discuss his takeaways and caring for patients with co-occurring mental illness and substance use disorder.